• Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drug

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients.

Rebecca Robbins
Author: Rebecca Robbins

Written by

Rebecca Robbins

in

Clinical Trials, CVS Caremark Corporation, Drugs (Pharmaceuticals), Eli Lilly and Company, GLP-1 RAs (Drug), Health Insurance and Managed Care, Novo Nordisk A/S, Obesity, Prices (Fares, Fees and Rates), Research
←Transportation Secretary Gets Pressed Over Repeated Airport Failures And Musk’s FAA Cuts
Johnny Rodriguez, Country Music Star, Dead at 73→

More posts

  • WATCH: How a new drug could lengthen lives of pancreatic cancer patients

  • Candidates face off on affordability in final California gubernatorial debate

  • Read the full transcript: Secretary of State Marco Rubio interviewed by ‘NBC Nightly News’ anchor Tom Llamas

  • Claudine Longet, the French starlet who fatally shot Olympic skier Spider Sabich, dies at 84

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube